Jakub Hlavka

Title(s)Research Fellow
SchoolUSC Sol Price School of Public Policy
Address1845 N. Soto Street
Health Sciences Campus
Los Angeles CA 90032
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Pardee RAND Graduate School, Santa Monica, CAPhDPublic Policy Analysis: Health Economics
    Georgetown University , Washington D.C.MA International Affairs, Technology Policy
    University of Economics, Prague, Czech RepublicBSc.International Trade
    Collapse Awards and Honors
    Aspen Institute Central Europe2017Aspen Young Leader
    St Gallen Symposium2015Leader of Tomorrow

    Collapse Overview 
    Collapse Overview
    Jakub Hlávka, PhD, is an Adjunct Clinical Associate Professor of Population and Public Health Sciences at the USC Keck School of Medicine, Assistant Professor of Public Economics at Masaryk University, and a Fellow at the Schaeffer Center for Health Policy & Economics, University of Southern California. His research interests include innovative payment for healthcare, health system reform, emerging therapies and the study of inequality.

    Prof. Hlávka completed his PhD at the Pardee RAND Graduate School where he studied innovative payment approaches for emerging treatments like cell and gene therapies, specializing in cardiovascular conditions. At RAND, he also co-authored studies in national security, aerospace and emerging technologies and has served in research and consulting roles at the intersection of research finance, intellectual property, national security and governance at Genentech, the Fraunhofer Society, RAND Europe, Czech Government and the Czech Ministry of Finance. Dr. Hlávka holds degrees from Georgetown University and the University of Economics in Prague.

    Prof. Hlávka teaches graduate-level courses on health systems at the Keck School of Medicine at USC.

    Collapse ORNG Applications 
    Collapse Faculty Mentoring

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans. BioDrugs. 2023 Jul; 37(4):531-540. Yu T, Jin S, Li C, Chambers JD, Hlávka JP. PMID: 37004706; PMCID: PMC10287773.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    2. Scientists without borders: lessons from Ukraine. Gigascience. 2022 12 28; 12. Wolfsberger W, Chhugani K, Shchubelka K, Frolova A, Salyha Y, Zlenko O, Arych M, Dziuba D, Parkhomenko A, Smolanka V, Gümüs ZH, Sezgin E, Diaz-Lameiro A, Toth VR, Maci M, Bortz E, Kondrashov F, Morton PM, Labaj PP, Romero V, Hlávka J, Mangul S, Oleksyk TK. PMID: 37496156; PMCID: PMC10372202.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Remote opportunities for scholars in Ukraine. Science. 2022 Dec 23; 378(6626):1285-1286. Chhugani K, Frolova A, Salyha Y, Fiscutean A, Zlenko O, Reinsone S, Wolfsberger WW, Ivashchenko OV, Maci M, Dziuba D, Parkhomenko A, Bortz E, Kondrashov F, Labaj PP, Romero V, Hlávka J, Oleksyk TK, Mangul S. PMID: 36548425.
      View in: PubMed   Mentions:    Fields:    
    4. Macroeconomic consequences of the COVID-19 pandemic. Econ Model. 2022 Dec 21; 106147. Walmsley T, Rose A, John R, Wei D, Hlávka JP, Machado J, Byrd K. PMID: 36570545; PMCID: PMC9768433.
      View in: PubMed   Mentions: 6  
    5. Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge. Alzheimers Dement. 2023 05; 19(5):1800-1820. Handels RLH, Green C, Gustavsson A, Herring WL, Winblad B, Wimo A, Sköldunger A, Karlsson A, Anderson R, Belger M, Brück C, Espinosa R, Hlávka JP, Jutkowitz E, Lin PJ, Mendez ML, Mar J, Shewmaker P, Spackman E, Tafazzoli A, Tysinger B, Jönsson L, IPECAD modeling workshop 2020 participants. PMID: 36284403; PMCID: PMC10126209.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Access to Disease-Modifying Alzheimer's Therapies: Addressing Possible Challenges Using Innovative Payment Models. Value Health. 2022 Jul 05. Hlávka JP, Tysinger B, Yu JC, Lakdawalla DN. PMID: 35803845; PMCID: PMC9813270.
      View in: PubMed   Mentions:    Fields:    
    7. Addressing Challenges to Alternative Payment Models for New Alzheimer's Disease Therapies for US Commercial Payers. Pharmacoeconomics. 2022 07; 40(7):647-652. Hlávka JP, Lavelle TA, Neumann PJ, Lin PJ. PMID: 35553029; PMCID: PMC10372750.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. Impact of non-binding FDA guidances on primary endpoint selection in Alzheimer's disease trials. Alzheimers Dement (N Y). 2022; 8(1):e12280. Yu JC, Hlávka JP, Joe E, Richmond FJ, Lakdawalla DN. PMID: 35356740; PMCID: PMC8943597.
      View in: PubMed   Mentions:
    9. Crosswalk between the Mini-Mental State Examination and the Telephone Interview for Cognitive Status (TICS-27/30/40). Alzheimers Dement. 2022 11; 18(11):2036-2041. Hlávka JP, Yu JC, Lakdawalla DN. PMID: 35103408; PMCID: PMC10373741.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. The economics of alternative payment models for pharmaceuticals. Eur J Health Econ. 2021 Jun; 22(4):559-569. Hlávka JP, Yu JC, Goldman DP, Lakdawalla DN. PMID: 33725260; PMCID: PMC8169601.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    11. Clinical Outcome Measure Crosswalks in Alzheimer's Disease: A Systematic Review. J Alzheimers Dis. 2021; 83(2):591-608. Hlávka JP, Kinoshita AT, Fang S, Hunt A. PMID: 34334392; PMCID: PMC10382157.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    12. The Potential Benefits of Deferred Payment for a Hypothetical Gene Therapy for Congestive Heart Failure: A Cost-Consequence Analysis. Appl Health Econ Health Policy. 2020 10; 18(5):669-677. Hlávka JP, Mattke S, Wilks A. PMID: 32090302; PMCID: PMC7483141.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: Projecting the impact on the cost and wait times. Alzheimers Dement (Amst). 2020; 12(1):e12081. Mattke S, Cho SK, Bittner T, Hlávka J, Hanson M. PMID: 32832590; PMCID: PMC7434228.
      View in: PubMed   Mentions: 23  
    14. Outcome measures for oncology alternative payment models: practical considerations and recommendations. Am J Manag Care. 2019 12 01; 25(12):e403-e409. Hlávka JP, Lin PJ, Neumann PJ. PMID: 31860235; PMCID: PMC6927528.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    15. The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey. J Am Board Fam Med. 2019 Nov-Dec; 32(6):931-940. Lam J, Hlávka J, Mattke S. PMID: 31704763.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    16. Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer's Treatment. Rand Health Q. 2019 May; 8(3):2. Hlavka JP, Mattke S, Liu JL. PMID: 31205802; PMCID: PMC6557037.
      View in: PubMed   Mentions: 62  
    17. Biosimilar Cost Savings in the United States: Initial Experience and Future Potential. Rand Health Q. 2018 Mar; 7(4):3. Mulcahy AW, Hlavka JP, Case SR. PMID: 30083415; PMCID: PMC6075809.
      View in: PubMed   Mentions: 78  
    18. A New Model for Pricing Drugs of Uncertain Efficacy. NEJM Catalyst. 2018. Erik Snowberg Dana P. Goldman, Karen Van Nuys, Wei-Han Cheng, Jakub P. Hlávka, Luca Pani, Sylvain Chassang . View Publication.
    19. Toward a Sustainable Blood Supply in the United States. 2016. Andrew W Mulcahy, Kandice Kapinos, Brian Briscombe, Lori Uscher-Pines, Ritika Chaturvedi, Spencer R Case, Jakub Hlávka, Benjamin M Miller. View Publication.
    Jakub's Networks
    Concepts (42)
    Derived automatically from this person's publications.
    _
    Co-Authors (6)
    People in Profiles who have published with this person.
    _
    Similar People (59)
    People who share similar concepts with this person.
    _